{"id":644394,"date":"2010-01-26T15:13:07","date_gmt":"2010-01-26T20:13:07","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.762"},"modified":"2010-01-26T15:15:17","modified_gmt":"2010-01-26T20:15:17","slug":"pharmasset-further-refines-its-hepatitis-c-polymerase-inhibitor","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/644394","title":{"rendered":"Pharmasset Further Refines Its Hepatitis C Polymerase Inhibitor"},"content":{"rendered":"<p>An isomer of PSI -7851 (a polymerase inhibitor that has already demonstrated encouraging clinical results for Hepatitis C), Pharmasset believes that PSI-7977 would be more potent and better suited for manufacturing. Hence, Pharmasset has initiated a Phase 2a trial to test this substance on treatment na\u00efve participants with Hepatitis C genotype 1.<\/p>\n<p>Pharmasset Initiates Phase 2a Trial With PSI-7977, A Chirally Pure Isomer Of PSI-7851<\/p>\n<p>Article Date: 23 Jan 2010<\/p>\n<p>Pharmasset, Inc. (Nasdaq: VRUS) announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate various doses of PSI-7977 in combination with Pegasys (peginterferon alfa 2a) and Copegus (ribavirin) in patients with HCV genotype 1 who have not been treated previously.<\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.medicalnewstoday.com\/articles\/176924.php\">http:\/\/www.medicalnewstoday.com\/articles\/176924.php<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>An isomer of PSI -7851 (a polymerase inhibitor that has already demonstrated encouraging clinical results for Hepatitis C), Pharmasset believes that PSI-7977 would be more potent and better suited for manufacturing. Hence, Pharmasset has initiated a Phase 2a trial to test this substance on treatment na\u00efve participants with Hepatitis C genotype 1. Pharmasset Initiates Phase [&hellip;]<\/p>\n","protected":false},"author":288,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-644394","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2HDs","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/644394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/288"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=644394"}],"version-history":[{"count":0,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/644394\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=644394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=644394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=644394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}